First Major Study Ties Recreational Marijuana Laws To Spike In Cardiovascular Hospitalizations

According to the New York Post, recreational cannabis is now legal in 24 states, a milestone trumpeted by activists as a cultural and political triumph, yet emerging evidence suggests the celebration may be premature. A new peer-reviewed study indicates that the policy revolution around marijuana could be carrying a hidden cost in the form of increased cardiovascular illness, a concern that lawmakers and public health officials have largely downplayed amid the rush to normalize the drug.

The health risks associated with cannabis use have been documented for years, even as its public image has been softened by aggressive marketing and progressive advocacy. Short-term use can trigger anxiety, impair memory and cause dry mouth, while chronic consumption has been linked to lung and blood vessel damage and even “scromiting,” an increasingly reported syndrome of uncontrollable vomiting that can escalate into life-threatening neurological complications.

Now, a first-of-its-kind study published Thursday in BMJ Open has connected the dots between recreational cannabis legalization in the United States and a rise in hospital admissions for several serious cardiovascular diseases. “While several studies have examined the association of recreational cannabis legalisation on psychiatric conditions, substance use, emergency visits and traffic accidents, ours is the first study to examine the association with [cardiovascular] hospitalizations,” said researchers.

The team examined more than 50 million hospital discharge records from 2012 to 2018, providing a sweeping view of health trends before and after legalization. They found that admissions for atrial fibrillation (abnormal heart rhythm), heart failure and heart attacks climbed more rapidly after recreational cannabis laws took effect in the Western United States than in regions that kept the drug illegal.

Patients hospitalized for these conditions in legalization states skewed somewhat younger, with an average age of 51 compared with 55 in other regions. They were also more likely to live in higher-income ZIP codes (26% versus 19%) and less likely to identify as white, suggesting that legalization’s health impact is not confined to stereotypical users or marginalized groups.

Before legalization, hospital discharge rates for the cardiovascular conditions under review were actually lower in the Western region than in areas without recreational cannabis laws. After legalization, however, those rates accelerated, rising just over 2% faster for atrial fibrillation, nearly 4% faster for heart failure and just over 3% faster for heart attacks.

Cannabis may influence cardiovascular health through several biological pathways that are rarely highlighted in pro-legalization campaigns. These include increases in heart rate, fluctuations in blood pressure, blood clot formation and chest pain, all of which can be especially dangerous for older adults or those with underlying conditions.

Legalization itself has been associated with broader and more frequent cannabis use, particularly among older Americans who already face elevated cardiovascular risk. That pattern undercuts the narrative that legalization is primarily about decriminalizing youthful experimentation and instead points to a growing, mainstream consumer base that may be unknowingly courting medical danger.

Because Western states were the earliest adopters of recreational cannabis, beginning in 2014, researchers focused on 13 states in that region: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington and Wyoming. By 2018, more than 98% of residents in this region lived in or adjacent to a state with legal cannabis sales, creating a near-ideal natural experiment to assess how policy shifts reverberate through public health.

The study tracked hospitalization rates for acute heart failure, heart attack, atrial fibrillation/flutter, ischemic (blood clot) stroke, venous thromboembolism or VTE (deep vein blood clot) and ventricular tachycardia (fast heartbeat). To isolate the impact of legalization, the researchers established a baseline from the two years preceding legal sales and then compared Western trends with those in regions where recreational cannabis remained prohibited.

The authors stressed that their work is observational and comes with important limitations, including the inability to analyze each state individually, differentiate among methods of cannabis consumption or fully account for patterns of illegal use. Therefore, the study cannot definitively prove that legalization itself directly caused the uptick in cardiovascular hospitalizations, even though the timing and magnitude of the changes are difficult to ignore.

“While an observational study cannot prove causality, our findings point to potential adverse effects of recreation legalisation on population health,” said the researchers. “Globally, our findings support a cautious approach to legalization laws accompanied by data collection on [cardiovascular] outcomes.”

For policymakers who rushed to embrace marijuana as a harmless revenue stream and a social-justice talking point, the message is clear: a sober reassessment is overdue, and any future expansion of legalization should be grounded in rigorous health data rather than ideological enthusiasm.